If your gastroenterologist has prescribed Entyvio for Crohn's disease and you carry an Aetna plan, the short answer is that Aetna does generally cover Entyvio, but coverage is conditional. Aetna treats vedolizumab, the generic name for Entyvio, as a covered benefit when its medical necessity criteria are met, and it requires prior authorization before paying for the drug. Entyvio is an integrin receptor antagonist indicated in adults for moderately to severely active Crohn's disease, and it is a gut-selective therapy that blocks the alpha-4-beta-7 integrin involved in inflammation in the digestive tract. Whether your specific plan approves it depends on how well your treatment history and clinical documentation line up with Aetna's published rules. This article walks through how that coverage works.
How Aetna Documents Entyvio Coverage
Aetna, a CVS Health company, spells out what it will and will not pay for in documents called Clinical Policy Bulletins. The relevant one here is Aetna Clinical Policy Bulletin 0885 on Vedolizumab (Entyvio), which states that vedolizumab requires precertification and is considered medically necessary for the treatment of moderately to severely active Crohn's disease. That same bulletin requires the drug to be prescribed by or in consultation with a gastroenterologist for Crohn's disease. Aetna manages its pharmacy benefit through CVS Caremark and its specialty drugs through CVS Specialty, so the review of your Entyvio request may be handled by those affiliated entities depending on your plan. Reading the bulletin that applies to your situation is the most direct way to see the exact wording Aetna uses, because the bulletin is the standard the reviewer applies.
Medical Benefit Versus Pharmacy Benefit
Entyvio is given by intravenous infusion at weeks 0, 2, and 6, and then patients may remain on intravenous therapy or switch to a subcutaneous injection for maintenance. This dual format matters for coverage because infused drugs administered in a clinic typically fall under the medical benefit, while self-injected maintenance doses may run through the pharmacy benefit. Aetna's own Medicare Part B criteria document for Entyvio describes the intravenous form as a covered benefit for adults with moderately to severely active Crohn's disease when the drug is furnished incident to a physician's service and is not self-administered. The subcutaneous version was approved by the FDA for Crohn's maintenance therapy in April 2024 and may be processed differently. Confirming which benefit applies tells you whether your cost share is an infusion copay or a specialty pharmacy charge.
Prior Authorization and What Aetna Typically Asks For
Prior authorization is the central hurdle. Before Aetna pays, your gastroenterologist submits a request that documents your diagnosis and clinical picture, and the reviewer checks it against the policy bulletin. Notably, Aetna's bulletin frames vedolizumab as medically necessary based on disease severity rather than mandating a documented failure of a TNF blocker first for initial Crohn's approval, which differs from some insurers that impose strict step therapy. Even so, individual Aetna plans can layer on their own step-therapy or formulary rules, so your specific plan documents may still require you to have tried conventional treatment. A strong submission usually includes:
Your confirmed Crohn's diagnosis and disease activity
A record of prior medications tried, with dates and outcomes
The prescribing gastroenterologist's clinical rationale
Gathering this before the request goes in reduces back-and-forth and avoids preventable denials.
Why Entyvio Is Often a Reasonable Choice for Crohn's
Coverage reviewers weigh whether a drug is appropriate for the condition, and Entyvio has solid evidence behind it. In the GEMINI 2 trial published in the New England Journal of Medicine, 39.0% of patients on vedolizumab every 8 weeks were in clinical remission at week 52 compared with 21.6% on placebo. Professional guidance also supports its use. The 2025 AGA Living Clinical Practice Guideline on the pharmacologic management of moderate-to-severe Crohn's disease reviews vedolizumab among the advanced therapies used to treat the disease. The gut-selective mechanism that limits its action largely to the intestine is one reason clinicians often consider it, particularly for patients who want to avoid broader immune suppression. None of this guarantees approval, but it gives your prescriber a documented, evidence-based case to present to Aetna.
What to Do If Aetna Denies Your Entyvio Request
A denial is not the end of the process. If Aetna declines to cover Entyvio, you have the right to appeal, and you should ask for the specific reason in writing so the appeal can address it directly. For Medicare members, Medicare describes a formal appeals process you can use when you disagree with a coverage decision by your plan, and commercial Aetna plans have parallel internal appeal levels followed by an independent external review. The strongest appeals attach a letter of medical necessity from your gastroenterologist, your relevant medical records, and supporting clinical evidence. Because the Aetna bulletin spells out the precise criteria a request must meet, matching your appeal language to those criteria is a practical way to respond. Persistence matters here, since denials are frequently overturned when the documentation is complete and clearly tied to the policy.
Bringing It Together
Aetna covers Entyvio for Crohn's disease under defined conditions rather than automatically. The drug is an FDA-approved, gut-selective therapy for moderately to severely active Crohn's disease, and Aetna's Clinical Policy Bulletin treats it as medically necessary when its criteria are met and prior authorization is obtained. Whether your claim is paid through the medical or pharmacy benefit, the outcome depends heavily on documentation, which means your treatment history, your gastroenterologist's rationale, and the clinical evidence all carry weight. The most reliable path is to read the bulletin and your own plan materials, confirm what your plan requires, and assemble a complete request before it is submitted. If a denial arrives, an organized, criteria-matched appeal remains a realistic route to coverage.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.